Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors
J Clin Oncol
.
2013 Mar 1;31(7):976-7.
doi: 10.1200/JCO.2012.47.0351.
Epub 2013 Jan 28.
Authors
Julien Hadoux
,
Michel Ducreux
PMID:
23358990
DOI:
10.1200/JCO.2012.47.0351
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dacarbazine / administration & dosage*
Dacarbazine / analogs & derivatives*
Female
Humans
Male
Neuroendocrine Tumors / drug therapy*
Substances
Dacarbazine